Equities in Focus - Supernus Pharmaceuticals Inc (NASDAQ:SUPN), NxStage Medical, Inc. (NASDAQ:NXTM), Ormat Technologies, Inc. (NYSE:ORA)

Supernus Pharmaceuticals Inc (NASDAQ:SUPN), a specialty pharmaceutical company, swung to a Q3 profit from a loss in the same period a year ago and beat Street forecasts on total revenue, fueled by prescription growth. The company reported Q3 adjusted EPS of $0.39, up from a loss of $0.78 per share in Q3 2013 but missing analyst estimates of $0.44 in earnings. Total revenues of $52.48 million were up from $1.25 million in Q3 2013 and topped analyst projections of $43.17 million for the quarter. The company raised revenue guidance from approximately $105 million to a range of $115 million to $118 million for 2014 and reaffirmed a prediction of cash flow break even by end of year. The Street is at $104.4 million for full year 2014 revenue. Shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) are trading within a 52-week range of $6.50 - $11.47.Click here for a free comprehensive Trend Analysis ReportNxStage Medical, Inc. (NASDAQ:NXTM) says the first matched cohort study of its kind shows patients using products like the company's frequent home hemodialysis (HHD) have a 16% lower risk of death, 8% lower risk of hospitalization, and 38% lower risk of therapy attrition than peritoneal dialysis (PD) patients. The study, conducted by the Chronic Disease Research Group (CDRG), will be presented orally and in a poster session at the American Society of Nephrology's Kidney Week 2014 this week.In addition to CDRG findings, the FREEDOM Study, a research project funded by NxStage Medical, Inc. (NASDAQ:NXTM), showed frequent home hemodialysis treatment for ESRD patients is associated with a more positive and sustained impact on quality of life than patients' prior therapies. Together, these findings show that improved survival, better hospitalization rate, and longer therapy retention on HHD therapy may translate to a patient's perception of their overall quality of life and general well-being, the company claims.Click here for a free comprehensive Trend Analysis ReportOrmat Technologies, Inc. (NYSE:ORA), the provider of energy recovery services said it would acquire its parent Ormat Industries through an exchange of shares. Ormat Industries currently owns about 60% or ORA's outstanding common stock. Ormat Technologies, Inc. (NYSE:ORA), said the transaction would benefit shareholders by enhancing liquidity via an increase in shares outstanding, and could increase trading volume and equity coverage.Under the terms of the deal, which would be handled as a merger agreement, shareholders of current parent Ormat Industries would receive 0.2592 shares in the combined company for each share they currently own in Ormat Industries, or an aggregate of 30.3 million shares. Upon closing of the transaction, existing ORA shareholders would own about 38% of the combined company, and former parent company shareholder would own about 62%. ORA said the proposed transaction was expected to close in Q115, subject to the approval of shareholders, and regulatory and Israeli court approvals.Click here for a free comprehensive Trend Analysis Report